ArriVent BioPharma, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) sum-of-the-parts, since the company is pre-revenue and a standard operating DCF doesn't apply. Pipeline value: assumed risk-adjusted peak annual FCF (already probability-weighted for trial/regulatory success) of ~$300M at peak (~2033), capitalized at an 8x exit-FCF multiple = $2.4B terminal value, discounted back 7 years at a 12% biotech discount rate to ~$1,086M. Net cash of $373.1M (June 30, 2026) is added on top. Total value = $1,086M + $373M = $1,459M / 49.31M diluted shares = $29.50/share.

Reasoning: As a clinical-stage, pre-revenue biopharma, ArriVent has no current FCF to discount, so a probability/risk-adjusted NPV of its lead pipeline asset (firmonertinib, already commercial in China via partner and in Phase 3 for ex-China indications) plus net cash is the standard and most defensible valuation framework.